SIRT6 overexpression can enhance glycolysis in erlotinib-sensitive NSCLC cells, while SIRT6 knockdown attenuates glycolysis in erlotinib-resistant NSCLC cells. Here, SIRT6 is linked to non-small cell lung carcinoma.